Article
Outcomes after combined modality therapy for EGFR-mutant and wild-type locally advanced NSCLC.
The oncologist - 1 Jan 2011
Mak Raymond H, Doran Elizabeth, Muzikansky Alona, Kang Josephine, Neal Joel W, Baldini Elizabeth H, Choi Noah C, Willers Henning, Jackman David M, Sequist Lecia V
Abstract excerpt
BACKGROUND: Epidermal growth factor receptor (EGFR) mutations identify a unique biological subtype of non-small cell lung cancer (NSCLC). Treatment outcomes for EGFR-mutant locally advanced NSCLC patients have not been well described. METHODS: We retrospectively examined outcomes after combined modality therapy including thoracic radiation therapy (RT) in 123 patients with locally advanced NSCLC and known EGFR...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.